Pentwater Capital Management Adds $2M in Medline Inc. ($MDLN)
Pentwater Capital Management has taken a new stake in Medline Inc., acquiring 50,000 shares worth $1.8 million.
Key Points
- Pentwater Capital Management opened a new position in Medline Inc. (MDLN) with 50,000 shares valued at $1.8 million as of May 15, 2026.
- Medline shares traded near $36.05 on Thursday with a market cap of $29.35 billion and a P/E ratio of 30.45.
- Analysts maintain bullish ratings with targets ranging from $40 to $62, while insider trades include significant selling activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Pentwater Capital Management has opened a new position in Medline Inc. (NASDAQ: MDLN), acquiring 50,000 shares valued at approximately $1.8 million. This move, reported in a recent SEC filing, marks a fresh investment for the firm as of the reporting period ending May 15, 2026.
Pentwater Capital Management vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Pentwater Capital Management's Medline Inc. Position
Pentwater Capital Management initiated a new stake in Medline Inc. by purchasing 50,000 shares. This strategic move reflects the firm's decision to invest approximately $1.8 million in the healthcare company, which focuses on medical instruments and supplies.
Other Institutional Activity in Medline Inc.
Several notable institutional investors have also adjusted their positions in Medline Inc. Carlyle Group Inc. reduced its holdings by 28.2 million shares, ending with 187.1 million shares valued at $8.33 billion, a 13.1% decrease. H&F Corporate Investors X, Ltd. similarly decreased its holdings by 13.1%, selling 13 million shares to hold 86.5 million shares worth $3.85 billion. On the other hand, FMR LLC increased its position by 10.2 million shares, now holding 36.6 million shares valued at $1.63 billion, marking a 38.7% increase. Capital Research Global Investors and Invesco Ltd. also boosted their holdings significantly, with Invesco Ltd. showing a remarkable 728.8% increase.
Medline Inc. Stock Up 11.8%
Shares of Medline Inc. traded near $36.05 on Thursday. The company boasts a market cap of $29.35 billion and a P/E ratio of 30.45, with a forward P/E of 20.81. Medline's stock has seen a 52-week range from $32.82 to $50.88. The company's 50-day moving average is $40.34, while its 200-day moving average is $42.48. Medline maintains a strong liquidity position with a current ratio of 4.41 and a quick ratio of 2.34, though it carries a debt-to-equity ratio of 65.31.
$MDLN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Medline Inc. reported revenue of $29.14 billion with a growth rate of 10.7%. The company's net margin stood at 3.3%, and it achieved a return on equity of 6.05%. Earnings per share came in at $1.14. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Medline Inc.
On June 16, 2026, Douglas Golwas, Chief Commercial Officer, sold 100,000 shares under a planned sale at an average price of $36.77. Amanda Laabs, Chief Product Officer, and Stephen Miller, Chief Operating Officer, each sold 1,889 shares at a price of $36.61 on June 15, 2026.
Analysts Set New Price Targets
On June 3, 2026, Baird maintained a 'buy' rating on Medline Inc. with a $45 price target. Similarly, Barclays maintained its 'buy' rating with the same target. BNP Paribas kept a 'hold' rating with a $40 target on May 14, 2026. The consensus among 27 analysts is a 'buy' rating, with a mean target price of $51.15.
About Medline Inc.
Medline Inc., headquartered in Northfield, Illinois, is a leading manufacturer and distributor of medical supplies and equipment. The company operates through its Medline Brand and Supply Chain Solutions segments, providing a wide range of products from surgical solutions to lab diagnostics. Founded in 1966, Medline serves healthcare facilities across the globe and employs approximately 45,000 people under the leadership of CEO James M. Boyle.
Bottom Line
Pentwater Capital Management's new position in Medline Inc. highlights the firm's interest in the healthcare sector. Investors often track such institutional moves for insights into potential growth areas. It's important to remember that 13F filings reflect holdings at the end of the quarter and may not represent current positions.
Get Medline Inc. alerts
New 13F filings, insider trades, and analyst moves on $MDLN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.